Sarepta Therapeutics (NASDAQ:SRPT) Given New $20.00 Price Target at JPMorgan Chase & Co.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price cut by investment analysts at JPMorgan Chase & Co. from $28.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 42.15% from the stock's previous close.

SRPT has been the subject of a number of other research reports. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research report on Wednesday, June 25th. Robert W. Baird lifted their target price on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Royal Bank Of Canada cut their price objective on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research report on Thursday. Finally, Mizuho cut their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $55.33.

Sarepta Therapeutics Stock Down 36.0%

NASDAQ SRPT opened at $14.07 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The stock has a market capitalization of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. Sarepta Therapeutics has a 1 year low of $11.95 and a 1 year high of $150.48. The business's 50-day moving average is $28.42 and its 200 day moving average is $67.58.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $61,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 300 shares in the last quarter. Finally, Hurley Capital LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $76,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.